CHKA and neoplasm: When concomitant treatment with liposomal clodronate was applied against TAMs, no obvious anti-tumor effect of sorafenib+CKI was detected anymore in comparison with liposomal clodronate, indicating that mechanism of action of sorafenib is more likely associated with immunomodulatory activity of TAMs [260].